LFMD · Lifemd, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $194.06M | $212.45M | $152.55M | $119.03M | $92.88M | $37.29M |
| Cost of Revenue | $27.71M | $24.07M | $18.90M | $18.67M | $18.00M | $8.91M |
| Gross Profit | $166.34M | $188.39M | $133.65M | $100.37M | $74.88M | $28.39M |
| R&D | - | - | - | - | - | - |
| SG&A | $57.94M | $72.66M | $51.69M | $46.96M | $39.57M | $42.21M |
| Total Operating Expenses | $174.01M | $204.53M | $148.14M | $143.81M | $129.18M | $86.21M |
| D&A | $865.5K | $488.0K | $204.0K | $161.9K | $13.6K | - |
| Operating Income | ($7.67M) | ($16.14M) | ($14.49M) | ($43.45M) | ($54.30M) | ($57.82M) |
| Interest Expense | $1.36M | $2.18M | $2.60M | $1.28M | $3.02M | $1.67M |
| Income Tax | $45.7K | $402.0K | $428.0K | $360.7K | $7.7K | $122.5K |
| Net Income | $14.35M | ($18.88M) | ($20.60M) | ($45.54M) | ($60.90M) | ($58.65M) |
| EPS - Basic | $0.25 | - | - | - | - | - |
| EPS - Diluted | $0.25 | - | - | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.65M | $35.00M | $33.15M | $3.96M | $41.33M | $9.18M |
| Accounts Receivable | $9.31M | $8.22M | $5.28M | $2.83M | $980.1K | $648.4K |
| Inventory | $2.77M | $2.80M | $2.76M | $3.70M | $1.62M | $1.26M |
| Accounts Payable | $14.15M | $16.01M | $11.08M | $10.11M | $9.06M | - |
| Current Assets | $51.83M | $48.73M | $42.60M | $11.31M | $44.92M | $12.06M |
| Total Assets | $70.41M | $72.46M | $58.48M | $25.67M | $49.92M | $13.05M |
| Current Liabilities | $41.57M | $60.26M | $34.78M | $31.37M | $22.83M | $13.49M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $47.25M | $76.51M | $52.91M | $32.97M | $24.10M | $13.88M |
| Stockholders' Equity | $23.16M | ($5.49M) | $3.51M | ($11.40M) | $22.74M | ($2.30M) |
| Retained Earnings | ($228.60M) | ($236.25M) | ($214.27M) | ($190.56M) | ($141.92M) | ($80.15M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $8.28M | $17.51M | $8.82M | ($22.94M) | ($33.09M) | ($12.13M) |
| Investing Cash Flow | $6.91M | ($11.54M) | ($8.73M) | ($13.91M) | ($3.40M) | ($798.1K) |
| Financing Cash Flow | ($13.41M) | ($4.12M) | $29.10M | ($528.2K) | $68.64M | $21.00M |
| CapEx | $1.87M | $1.49M | $203.8K | $366.6K | $247.4K | - |
| Free Cash Flow | $6.41M | $16.02M | $8.62M | ($23.30M) | ($33.33M) | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 85.7% | 88.7% | 87.6% | 84.3% | 80.6% | 76.1% |
| Operating margin | -4.0% | -7.6% | -9.5% | -36.5% | -58.5% | -155.0% |
| EBITDA margin | -3.5% | -7.4% | -9.4% | -36.4% | -58.5% | - |
| Net margin | 7.4% | -8.9% | -13.5% | -38.3% | -65.6% | -157.3% |
| Free cash flow margin | 3.3% | 7.5% | 5.6% | -19.6% | -35.9% | - |
| FCF / Net income | 0.45 | -0.85 | -0.42 | 0.51 | 0.55 | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 29.9% | 34.2% | 33.9% | 39.5% | 42.6% | 113.2% |
| Effective tax rate | 0.3% | - | - | - | - | - |
| Return on assets | 20.4% | -26.1% | -35.2% | -177.4% | -122.0% | -449.3% |
| Return on equity | 62.0% | 344.2% | -587.6% | 399.6% | -267.8% | 2547.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.25 | 0.81 | 1.22 | 0.36 | 1.97 | 0.89 |
| Quick ratio | 1.18 | 0.76 | 1.15 | 0.24 | 1.90 | 0.80 |
| Cash ratio | 0.79 | 0.58 | 0.95 | 0.13 | 1.81 | 0.68 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -5.6x | -7.4x | -5.6x | -34.1x | -18.0x | -34.7x |
| Equity multiplier | 3.04 | -13.21 | 16.68 | -2.25 | 2.20 | -5.67 |
| Liabilities / Assets | 0.67 | 1.06 | 0.90 | 1.28 | 0.48 | 1.06 |
| Efficiency | ||||||
| Asset turnover | 2.76 | 2.93 | 2.61 | 4.64 | 1.86 | 2.86 |
| Inventory turnover | 9.99 | 8.60 | 6.85 | 5.04 | 11.13 | 7.05 |
| Days sales outstanding | 18d | 14d | 13d | 9d | 4d | 6d |
| Days inventory outstanding | 37d | 42d | 53d | 72d | 33d | 52d |
| Days payable outstanding | 186d | 243d | 214d | 198d | 184d | - |
| Cash conversion cycle | -132d | -186d | -148d | -117d | -147d | - |
| Valuation | ||||||
| P / E | 13.6x | - | - | - | - | - |
| P / B | 6.6x | - | 76.9x | - | 4.6x | - |
| P / S | 0.8x | 1.0x | 1.8x | 0.5x | 1.1x | 2.5x |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -8.7% | 39.3% | 28.2% | 28.2% | 149.0% | 199.1% |
| Revenue CAGR (3y) | 17.7% | 31.8% | 59.9% | 112.1% | 123.5% | 94.7% |
| Revenue CAGR (5y) | 39.1% | 76.3% | 78.9% | 88.1% | 77.7% | 98.2% |
| Gross profit growth (YoY) | -11.7% | 41.0% | 33.2% | 34.0% | 163.8% | 208.6% |
| Operating income growth (YoY) | 52.5% | -11.4% | 66.7% | 20.0% | 6.1% | -1900.9% |
| Net income growth (YoY) | - | 8.3% | 54.8% | 25.2% | -3.8% | -1769.4% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -60.0% | 86.0% | - | 30.1% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | - | -132.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$194.06M totalTelehealth Subscription Revenue$113.27M · 58.4%
Telehealth$80.79M · 41.6%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-0.03
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Services-Offices & Clinics of Doctors of Medicine
Comparing LifeMD against the 5 most active filers in the same SIC group.